WSJ
02 Jun 2026, 08:45 UTC · 2h ago
Abivax Shares Plunge After Company Reports Adverse Events in Key Drug Trial
Search tags
WSJ
02 Jun 2026, 08:45 UTC · 2h ago
Search tags
Story key points
2 claims · impact-rated
Some patients in a late-stage clinical trial for a bowel-disease drug developed cancer. — Cancer occurrences in late-stage trials typically trigger severe regulatory scrutiny and can jeopardize FDA approval.
-0.60The biotech company claims the cancer cases were unrelated to the treatment. — Company assertions of non-causality attempt to mitigate the negative impact on the drug's safety profile and stock price.
+0.30Ticker attribution
Model heads
No ticker sentiment head found.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Browse live screeningsContinue reading
6 related stories
Impact vectors
6 dimensions · 9 clusters
Market reaction
0 bid · 10 offered
No stock impact ranking available yet.
Proactive Investors
2h ago
